Promoting an increased awareness and standardized approaches in diagnosing and treating peripheral artery disease


Medical Therapy – All PAD Patients

Step 1 is relevant for all patients with PAD regardless of severity or comorbidity. All patients should be counseled on diet and exercise, be taught about home-based exercise and/or referred to supervised exercise where available, should stop smoking, and should have optimized blood pressure and cholesterol levels. Data from the HOPE trial demonstrated a reduction in MACE with ramipril, an angiotensin-converting enzyme inhibitor (ACEi) with consistent benefit in patients with PAD. Therefore, there is preference to use ACEi therapy, particularly in patients with diabetes. Patients with PAD and hypertension may need more than one agent. Beta blockers are safe to use in PAD if there is an indication (e.g. concomitant coronary disease). Selection of antihypertensive agents should be similar to that for blood pressure control in patients with atherosclerosis.

Cholesterol lowering has shown benefit in patients with atherosclerosis and specifically in patients with PAD. The Heart Protection Study demonstrated that simvastatin (vs. placebo) reduced major adverse cardiovascular events in a broad population with consistent benefit in those with PAD. A subsequent analysis in the PAD population showed a reduction in peripheral revascularizations. In addition, smaller studies have shown functional improvements with statins. Non-randomized data from the REACH registry suggest that statin therapy reduces amputation in patients with PAD. The FOURIER trial demonstrated that adding a PCSK9 inhibitor to statin therapy resulted in significant reductions in MACE and MALE in patients with PAD. These benefits were evident regardless of whether there was concomitant symptomatic coronary or cerebrovascular disease. Importantly, the benefits of reducing LDL-C for MACE and MALE extended to very low levels of LDL-C (<10 mg/dL) with no imbalance of adverse events or safety issues. The broad benefits in PAD for this therapy translated to a number needed to treat for MACE or MALE for 2.5 years of 16. Adherence can be an issue with all therapies and it is important to provide education, reinforce the benefits of therapy at each visit, answer questions, and monitor targets.


Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014; 168: 682-689

Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007; 45: 645-654; discussion 653-4.

Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC,Jr, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL, REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014; 35: 2864-2872.

Dosluoglu HH, Davari-Farid S, Pourafkari L, Harris LM, Nader ND. Statin use is associated with improved overall survival without affecting patency and limb salvage rates following open or endovascular revascularization. Vasc Med. 2014; 19: 86-93.

Westin GG, Armstrong EJ, Bang H, Yeo KK, Anderson D, Dawson DL, Pevec WC, Amsterdam EA, Laird JR. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol. 2014; 63: 682-690.

Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018; 137: 338-350.